Novotech CRO Signs Collaboration with Phramongkutklao Hospital in Bangkok, Thailand for Early Phase Studies

September 28, 2018

Company News Release

Asia-Pacific specialist CRO Novotech announced today it has signed a collaboration agreement with the Phramongkutklao Hospital in Bangkok, Thailand, and its dedicated Clinical Research Centre.http://www.pmk.ac.th/   Thailand has a population of 67.7 million people, with 34% living in urban areas like Bangkok.   The agreement was signed by Col. Ouppatham  Supasyndh, M.D., Head of Clinical Research Center, Phramongkutklao Hospital and Chayanontchaimongkol Boonchaliew, Country Manager of Novotech Clinical Research Thailand. Ltd. (see image attached)   As part of the agreement Novotech CRO will bring relevant early phase studies to the hospital’s Clinical Research Centre for access to the hospital’s leading investigators and clinical staff to support research.    On average, Novotech timelines for regulatory and IRB approval is currently at 4-5 months.   In addition, the hospital will: ·      assist with feasibility assessments ·      identify potential patients at the 1,200 bed facility ·      work closely with Novotech to efficiently start-up studies    Novotech works in partnership with the leading medical institutions across Asia to accelerate quality clinical research for its sponsors. Novotech has now signed 10 strategic collaborations with hospitals and research in the region.     The Phramongkutklao Hospital collaboration is designed to give Novotech clients faster start-up times, access to a vast patient pool, advanced clinical screening, as well as leading principal investigators.   The hospital has a number of key centres of excellence including:

  • Cancer Center

  • Trauma Center

  • Sirindhorn Heart Center

  • Organ Transplantation Center

  • Military Medicine Center

  Novotech Executive Director, Asia Operations Dr. Yooni Kim said Bangkok is rapidly growing region so there is with a real focus on delivery of advanced medical care and facilities.   “The MOU means Novotech will have dedicated clinical experts within the hospital to support and prioritise rapid clinical processes for Novotech biopharma clients,” Dr. Kim said.   Dr. Kim said: There are many compelling reasons to consider Bangkok for clinical research:

  • Large patient population

  • Few competing trials

  • Efficient regulatory system

  • Highly qualified and educated medical professionals

  • Low operational costs

  • Well supported IT infrastructure

  • High level of GCP compliance

  • Efficient trial management and logistics infrastructure.

  “Novotech is known as the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region. We have offices and teams on the ground as well as MOUs and long-term collaboration relationships with major hospitals that directly benefit our clients.”   “Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets.”   “The Novotech team is well positioned across the region to access the more than 1.4 billion people living in urban areas, which is a key factor in the decision by sponsors to include the Asia-Pacific in their global studies.”   Novotech was established in 1996, headquartered in Australia with offices in 11 countries across the region, and MOUs with major health providers.   

About Novotech

 - 

https://novotech-cro.com/welcome


Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region. 
  Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.   

For RFP enquiries:

 Please fill out the form available at 

www.novotech-cro.com/contact-us-0

 

Image:

https://www.dropbox.com/s/grxk62wafhqmucu/image001.jpg?dl=0 Caption: The agreement was signed by Col. Ouppatham  Supasyndh, M.D., Head of Clinical Research Center, Phramongkutklao Hospital and Chayanontchaimongkol Boonchaliew, Country Manager of Novotech Clinical Research Thailand. Ltd.   Media Contact Susan Fitzpatrick-Napier 

communications@novotech-cro.com

AU: +61 2 8218 2144  USA: +1 415 951 3228 Asia: +65 3159 3427

Related Content:

News